Quest Diagnostics to Speak at the William Blair 45th Annual Growth Stock Conference
SECAUCUS, N.J., May 16, 2025 /PRNewswire/ — Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a presentation at the William Blair 45th Annual Growth Stock Conference in Chicago on Tuesday, June 3, 2025, at 11:00 a.m. Eastern Time.
The presentation session will be webcast live during the conference on the company's investor relations page, which can be accessed at ir.QuestDiagnostics.com. In addition, the archived webcast will be available within 24 hours after the conclusion of the live event and will remain available until July 3, 2025.
About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our more than 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 hours ago
- Malaysian Reserve
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FLS, KNW, ELEV, CRKN on Behalf of Shareholders
NEW YORK, June 9, 2025 /PRNewswire/ — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Flowserve Corporation (NYSE: FLS)'s merger with Chart Industries, Inc. Upon completion of the proposed transaction, Flowserve shareholders will own approximately 46.5% of the combined company. If you are a Flowserve shareholder, click here to learn more about your rights and options. Know Labs, Inc. (NYSE American: KNW)'s sale to Goldeneye 1995 LLC. If you are a Know Labs shareholder, click here to learn more about your legal rights and options. Elevation Oncology, Inc. (NASDAQ: ELEV)'s sale to Concentra Biosciences, LLC. Under the terms of the proposed transaction, Elevation shareholders will receive $0.36 in cash per share, plus one non-tradeable contingent value right representing the right to receive: (i) 100% of the closing net cash in excess of $26.4 million; and (ii) 80% of any net proceeds received within five years following closing from any disposition of EO-1022 that occurs within one year following closing. If you are an Elevation shareholder, click here to learn more about your rights and options. Crown Electrokinetics Corp. (OTCMKTS: CRKN)'s sale to Crown EK Acquisition LLC for $3.15 per share. If you are a Crown Electrokinetics shareholder, click here to learn more about your rights and options. Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@ or zhalper@ Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information:Halper Sadeh LLCDaniel Sadeh, Halper, Esq.(212) 763-0060sadeh@
The Star
3 hours ago
- The Star
NIH scientists speak out over estimated $12 billion in Trump funding cuts
(Reuters) -Dozens of scientists, researchers and other employees at the U.S. National Institutes of Health issued a rare public rebuke Monday criticizing the Trump administration for major spending cuts that 'harm the health of Americans and people across the globe,' politicize research and 'waste public resources.' More than 60 current employees sent their letter to NIH director Dr. Jay Bhattacharya, U.S. Health Secretary Robert F. Kennedy Jr. and members of Congress who oversee NIH. Bhattacharya is scheduled to testify Tuesday at the U.S. Senate appropriations committee about his agency's budget. Overall, more than 340 current and recently terminated NIH employees signed the letter, about 250 of them anonymously. In their letter, NIH staff members said the agency had terminated 2,100 research grants totaling about $9.5 billion and an additional $2.6 billion in contracts since President Donald Trump took office Jan. 20. The contracts often support research, from covering equipment to nursing staff working on clinical trials. These terminations "throw away years of hard work and millions of dollars" and put patient health at risk, the letter said. NIH clinical trials "are being halted without regard to participant safety, abruptly stopping medications or leaving participants with unmonitored device implants." In a statement shared with Reuters, Bhattacharya said the employees' letter "has some fundamental misconceptions about the policy directions the NIH has taken in recent months ... Nevertheless, respectful dissent in science is productive. We all want the NIH to succeed." In prior remarks, Bhattacharya has pledged support for Kennedy's Make America Healthy Again agenda, and he has said that means focusing the federal government's "limited resources" directly on combating chronic diseases. At his Senate confirmation hearings in March, Bhattacharya said he would ensure scientists working at NIH and funded by the agency have the necessary resources to meet its mission. NIH is the world's largest public funder of biomedical research and has long enjoyed bipartisan support from U.S. lawmakers. The Trump administration has proposed cutting $18 billion, or 40%, from NIH's budget next year, which would leave the agency with $27 billion. Nearly 5,000 NIH employees and contractors have been laid off under Kennedy's restructuring of U.S. health agencies, according to NIH staff. A spokesperson for the U.S. Department of Health and Human Services, which oversees NIH, said the agency's staffing must evolve to meet changing priorities and to ensure good use of taxpayer dollars. The official also defended NIH's funding decisions, saying the agency was "working to remove ideological influence from the scientific process." Dr. Jenna Norton, a program director within NIH's division of kidney, urologic and hematologic diseases, was one of 69 current employees who signed the letter as of early Monday. She said speaking out publicly was worth the risk to her career and family. "I am much more worried about the risks of not speaking up," Norton said. "There are very real concerns that we're being asked to do likely illegal activities, and certainly unethical activities that breach our rules." The organizers of the letter allowed people employed at the NIH as of Jan. 20 to sign. They said 258 of the 342 people who signed the letter currently work at NIH, while others were recently terminated as probationary workers or 'subject to reductions in force.' In the letter, Norton and other NIH employees asked Bhattacharya to restore grants that were delayed or terminated for political reasons, where officials ignored peer review to "cater to political whims." They wrote that Bhattacharya had failed to uphold his legal duty to spend congressionally appropriated funds. One program director at the NIH's National Cancer Institute, who asked not to be identified for fear of retaliation, said she has repeatedly been asked to cancel research grants for no valid reason and in violation of agency rules. She said she fears she could become the target of lawsuits from grantees challenging those decisions. Dr. Benjamin Feldman, a staff scientist and core director at NIH's Institute of Child Health and Human Development, said he and other researchers want to work with Bhattacharya on reversing the cuts and restoring the NIH as a "beacon for science around the world." "This is really a hit to the whole enterprise of biomedical research in the United States," Feldman said. Dr. Ian Morgan, a postdoctoral fellow at the NIH, signed the letter and said he has heard from university researchers about patients losing access to novel cancer treatments in clinical trials due to the uncertainty over NIH funding. He also worries about the long-term effect from gutting NIH's investment in basic science research that can lead to lifesaving treatments years later. The NIH employees, based in Bethesda, Maryland, named their dissent the "Bethesda Declaration," modeled after Bhattacharya's Great Barrington Declaration in 2020 that called on public health officials to roll back lockdowns during the COVID-19 pandemic. "Our hope is that by modeling ourselves after the Great Barrington Declaration that maybe he'll see himself in our dissent," Norton said. (Reporting by Chad Terhune in Los Angeles; Editing by Michele Gershberg, Chizu Nomiyama and David Gregorio)
Malaysian Reserve
4 hours ago
- Malaysian Reserve
123Invent Inventor Develops Improved Bra for Curvier Women
PITTSBURGH, June 9, 2025 /PRNewswire/ — 'As a curvier woman, I hated the discomfort associated with wearing a traditional bra. I wanted to create a more comfortable option for me, my daughter, and other women with curves,' said an inventor, from Wagga, NSW, Australia, 'so I invented the CroBra (by Char). My design provides added comfort and support, and the improved sizing guide helps you select the right size.' The patent-pending invention provides an improved bra option for curvier women. In doing so, it prevents the bra from riding up and digging into the skin. It also helps prevent bulging. As a result, it increases comfort and support. Additionally, the invention features a unique design that is easy to wear. The CroBra (by Char) is currently available for licensing or sale to manufacturers or marketers. For more information, visit Or contact Lidia Ilievski at 045-720-0678 or email info@
